Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)

PURPOSE: Angiosarcoma is a rare aggressive endothelial cell cancer with high mortality. Isolated reports suggest immune checkpoint inhibition efficacy in angiosarcoma, but no prospective studies have been published. We report results for angiosarcoma treated with ipilimumab and nivolumab as a cohort...

Descripción completa

Detalles Bibliográficos
Autores principales: Wagner, Michael J, Othus, Megan, Patel, Sandip P, Ryan, Chris, Sangal, Ashish, Powers, Benjamin, Budd, G Thomas, Victor, Adrienne I, Hsueh, Chung-Tsen, Chugh, Rashmi, Nair, Suresh, Leu, Kirsten M, Agulnik, Mark, Sharon, Elad, Mayerson, Edward, Plets, Melissa, Blanke, Charles, Streicher, Howard, Chae, Young Kwang, Kurzrock, Razelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330584/
https://www.ncbi.nlm.nih.gov/pubmed/34380663
http://dx.doi.org/10.1136/jitc-2021-002990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8330584/
https://www.ncbi.nlm.nih.gov/pubmed/34380663
http://dx.doi.org/10.1136/jitc-2021-002990

Ejemplares similares